These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 11208851)

  • 21. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
    Coleman RE
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].
    Shen G; Song ST; Jiang ZF; Bian SG; Xie GR; Wang YJ; Wang JJ
    Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):632-4. PubMed ID: 16438878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypercalcemia of malignancy.
    Body JJ
    Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
    Nussbaum SR; Warrell RP; Rude R; Glusman J; Bilezikian JP; Stewart AF; Stepanavage M; Sacco JF; Averbuch SD; Gertz BJ
    J Clin Oncol; 1993 Aug; 11(8):1618-23. PubMed ID: 8336198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
    Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
    J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pamidronate.
    Kellihan MJ; Mangino PD
    Ann Pharmacother; 1992 Oct; 26(10):1262-9. PubMed ID: 1421653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conventional treatment of hypercalcemia of malignancy.
    Davidson TG
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S8-15. PubMed ID: 11757206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.
    Atula ST; Tähtelä RK; Nevalainen JI; Pylkkänen LH
    Acta Oncol; 2003; 42(7):735-40. PubMed ID: 14690159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.
    Guest JF; Clegg JP; Davie AM; McCloskey E
    Curr Med Res Opin; 2005 May; 21(5):805-15. PubMed ID: 15969880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypercalcemia of malignancy remains a clinically relevant problem.
    Van Poznak C
    Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
    Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
    J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
    Young G; Shende A
    Med Pediatr Oncol; 1998 Feb; 30(2):117-21. PubMed ID: 9403021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zoledronic acid: new preparation. Just a me-too: no advance in hypercalcemia of malignancy.
    Prescrire Int; 2002 Oct; 11(61):140-1. PubMed ID: 12378744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
    Wright JD; Tergas AI; Ananth CV; Burke WM; Hou JY; Chen L; Neugut AI; Richards CA; Hershman DL
    Cancer Invest; 2015; 33(8):331-9. PubMed ID: 26068056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.